Accelerated TMS - moving quickly into the future of depression treatment
- PMID: 37217771
- PMCID: PMC10700378
- DOI: 10.1038/s41386-023-01599-z
Accelerated TMS - moving quickly into the future of depression treatment
Erratum in
-
Correction: Accelerated TMS - moving quickly into the future of depression treatment.Neuropsychopharmacology. 2024 Jan;49(1):297. doi: 10.1038/s41386-023-01714-0. Neuropsychopharmacology. 2024. PMID: 37640924 Free PMC article. No abstract available.
Abstract
Accelerated TMS is an emerging application of Transcranial Magnetic Stimulation (TMS) aimed to reduce treatment length and improve response time. Extant literature generally shows similar efficacy and safety profiles compared to the FDA-cleared protocols for TMS to treat major depressive disorder (MDD), yet accelerated TMS research remains at a very early stage in development. The few applied protocols have not been standardized and vary significantly across a set of core elements. In this review, we consider nine elements that include treatment parameters (i.e., frequency and inter-stimulation interval), cumulative exposure (i.e., number of treatment days, sessions per day, and pulses per session), individualized parameters (i.e., treatment target and dose), and brain state (i.e., context and concurrent treatments). Precisely which of these elements is critical and what parameters are most optimal for the treatment of MDD remains unclear. Other important considerations for accelerated TMS include durability of effect, safety profiles as doses increase over time, the possibility and advantage of individualized functional neuronavigation, use of biological readouts, and accessibility for patients most in need of the treatment. Overall, accelerated TMS appears to hold promise to reduce treatment time and achieve rapid reduction in depressive symptoms, but at this time significant work remains to be done. Rigorous clinical trials combining clinical outcomes and neuroscientific measures such as electroencephalogram, magnetic resonance imaging and e-field modeling are needed to define the future of accelerated TMS for MDD.
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
SVR does not report any competing interests. ARA does not report any competing interests. WMM is a member of the American Psychiatric Association (APA) Council on Research representing ECT and Neuromodulation Therapies. He receives funding from NIMH and NIA. Dr. McDonald is compensated as the chair of the DSMB for an NIA sponsored multicenter study. He is on the Board of Skyland Trail and 3Keys. He is a paid consultant for Sage Therapeutics and has been a consultant for Signant Health in the last five years. He has received past funding from the Stanley Foundation, Soterix, Neuronetics, NeoSync and Cervel Neurotherapeutics. He is a deputy editor of the American Journal of Psychiatry and on the editorial boards of the American Journal of Geriatric Psychiatry and Personalized Medicine in Psychiatry. He has endowed chair funded by the JB Fuqua Foundation. He is an employee of Emory University School of Medicine. NSP has received support (through VA contracts) for studies by Neurolief and Wave Neuro in the past 3 years. He serves on the Scientific Advisory Board of Pulvinar Neuro. The views expressed here are the authors’ and do not reflect the position or policies of the NIMH or VA.
Figures
References
-
- George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67:507–16. - PubMed
-
- O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62:1208–16. - PubMed
-
- Carpenter L, Aaronson S, Hutton TM, Mina M, Pages K, Verdoliva S, et al. Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder. Brain Stimul. 2021;14:173–80. - PubMed
-
- Prange AJ, Jr, Wilson IC, Rabon AM, Lipton MA. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry. 1969;126:457–69. - PubMed
-
- Altshuler LL, Frye MA, Gitlin MJ. Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry. 2003;53:691–700. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
